01 | LILLY CREATES A VACCINE M&A COMP SET Three same-day acquisitions give BD teams fresh infectious-disease prevention comps; pull vaccine-platform deal rows before pricing prevention assets. |
02 | RETATRUTIDE RESETS OBESITY BENCHMARKS TRIUMPH-1’s 28.3% mean weight loss at 80 weeks raises the bar for undifferentiated obesity assets; separate mechanism-differentiated from incremental incretin follow-ons. |
03 | DATROWAY SPLITS TROP2 ADC COMPS BY LABEL FDA approval in 1L metastatic TNBC creates a label-specific comparator; stop treating “TROP2 ADC” as a single comp bucket. |
Seller leverage ↑ Differentiated vaccine platforms with tolerability, manufacturing, or pathogen-risk logic. Lilly’s three deals are milestone-heavy but current-cycle. | Buyer leverage ↑ Against obesity assets without differentiated mechanism, route, body-composition, or tolerability claims. Retatrutide is now the benchmark problem. |
| LILLY VACCINE TRIOCurevo · LimmaTech · Vaccine Company | Event: May 26, 2026 M&A Comp |
Lilly announced agreements to acquire Curevo (up to $1.5B), LimmaTech Biologics (up to $780M), and Vaccine Company (up to $1.55B) to expand its infectious-disease portfolio across shingles tolerability, bacterial pathogens, and EBV-linked disease risk — all on the same day. All reported values are up-to consideration, not simple all-cash headlines. [PR Newswire ↗]
| HIGH | Three vaccine-platform deals announced same day; all disclose up-to rather than simple all-cash consideration. |
| HIGH | Assets span shingles tolerability, bacterial pathogens (AMR adjacency), and EBV-linked long-term disease risk. |
| MED | Creates a live strategic-buyer comp set for prevention assets with differentiated tech or pathogen-risk logic. |
| MED | Conclusion: Vaccine-platform sellers gain leverage when the story is differentiated prevention, not generic infectious-disease exposure. |
| Action: Model vaccine-platform acquisition comps using Curevo, LimmaTech, and Vaccine Company as current-cycle reference rows. | FACT: HIGH IMPL: MED |
| RETATRUTIDELilly TRIUMPH-1 · Obesity Phase 3 | Event: May 21, 2026 In-License Pricing |
Mean Wt Loss 28.3% | ≥30% Wt Loss 45.3% | Duration 80 weeks |
Lilly disclosed Phase 3 TRIUMPH-1 topline data establishing a new visible late-stage efficacy benchmark for obesity pharmacotherapy. Obesity assets priced against older incretin benchmarks now require mechanism-specific segmentation. [Lilly Investor ↗]
| HIGH | TRIUMPH-1 establishes a new disclosed late-stage efficacy benchmark for obesity pharmacotherapy. |
| HIGH | Obesity assets priced against older incretin benchmarks now require mechanism-specific segmentation. |
| MED | Oral delivery, amylin, glucagon, muscle-sparing, tolerability, or population-specific assets may preserve leverage. |
| MED | Conclusion: Obesity in-license screens should be rebuilt around differentiation, not generic category exposure. |
| Action: Reprice active and pipelined obesity in-license models against a retatrutide-adjusted benchmark; separate differentiated mechanisms from incremental incretin assets. | FACT: HIGH IMPL: MED |
| DATROWAYAstraZeneca / Daiichi · TROP2 ADC / 1L mTNBC | Event: May 22, 2026 ADC Comp |
FDA approved Datroway for adults with unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy. Disclosed efficacy: median PFS 10.8 vs. 5.6 months, median OS 23.7 vs. 18.7 months, ORR 64% vs. 30% versus chemotherapy. The PD-1-ineligibility restriction makes eligibility context central to comp use. [FDA ↗]
| HIGH | Defined 1L mTNBC label with PFS, OS, and ORR data disclosed against a chemotherapy comparator. |
| HIGH | Label restricted to patients not eligible for PD-1/PD-L1 inhibitors — eligibility is now a comp dimension. |
| MED | TROP2 ADC valuation requires segmentation by label, safety, patient eligibility, and tumor setting. |
| MED | Conclusion: Generic “TROP2 ADC” comps are too blunt for TNBC deal pricing. |
| Action: Reprice TNBC TROP2 ADC comps into label-specific buckets segmented by PD-1 eligibility, line of therapy, and safety profile. | FACT: HIGH IMPL: MED |
Buyer ask Keep meaningful value in clinical, regulatory, and commercial milestones for pre-approval vaccine assets. | Seller protection Preserve upside where differentiated tolerability, pathogen-risk, or prevention-of-long-term-sequelae is central to the value thesis. |
Buyer ask Tie value to differentiated profile, not just participation in the obesity category. | Seller protection Isolate differentiation claims — oral route, amylin/glucagon biology, muscle-sparing, tolerability, or specific population advantage — before accepting benchmark compression. |
Buyer ask Separate milestones by label, tumor type, and line of therapy. | Seller protection Preserve royalties or step-ups for tumor expansion and broader label optionality beyond TNBC. |
| Target | Why Now | Action |
Vaccine Platforms Differentiated prevention | Lilly created current-cycle prevention M&A comps across shingles, bacterial pathogens, and EBV | Add to screen |
Obesity (Mech-diff) Differentiated only | Retatrutide raises the benchmark for generic obesity exposure | Re-score pipeline |
TROP2 ADCs TNBC positioning | Datroway creates a label-specific comparator for 1L PD-1-ineligible TNBC | Reprice by label |
HDV / HBV Virology Rare, adjacent to HDV | Hepcludex sets first U.S. HDV reference therapy; remove non-differentiated follow-ons | Screen refresh |
| HEPCLUDEXFDA · First HDV approval | May 22 HDV Screen |
| VOXZOGOBioMarin · Hypochondroplasia Ph3 | May 20 Label Expansion |
| LYTENAVAOutlook Therapeutics · nAMD FDR win | May 26 Ophthalmic |
| SAC-TMTMerck / Kelun · TROP2 ADC Endometrial Ph3 | May 18 ADC Label Exp. |
| Item | Why not elevated |
EMA CHMP May opinions May 22, 2026 | Broad regulatory relevance but action is diffuse across unrelated classes; keep out of TOP unless a single comp set moves. |
Regeneron fianlimab melanoma miss May 15, 2026 | Useful for LAG-3 melanoma comp cleanup, but outside the core current-cycle window. |
Enhertu early breast cancer approvals May 15, 2026 | Better used as a precedent-table row unless the ADC thesis is broadened beyond TNBC/TROP2. |
| Asset / Deal | Class | Terms / Outcome | Use As |
Curevo / Lilly Shingles vaccine | Vaccine / Prevention | Up to $1.5B cash incl. upfront + milestones | Vaccine tolerability-differentiation comp [↗] |
LimmaTech / Lilly Bacterial-pathogen vaccines | Vaccine / AMR | Up to $780M reported transaction value | AMR / prevention-platform comp |
Vaccine Company / Lilly EBV vaccine platform | Vaccine / Viral EBV | Up to $1.55B cash incl. upfront + milestones | Viral-pathogen prevention comp |
Datroway FDA approval AstraZeneca / Daiichi | TROP2 ADC / 1L mTNBC | FDA-approved label PFS, OS, ORR disclosed | Label-specific ADC comparator |
Hepcludex FDA approval HDV / rare virology | Antiviral / HDV-HBV | First FDA-approved chronic HDV therapy | Reference standard for follow-on HDV assets |
Named claim Liminatus described its proposed InnocsAI merger as having an implied transaction value of approximately $320M. | Disclosed reality Consideration is 1.6B newly issued shares at $0.20/share plus CVRs. SEC filing names Liminatus CEO as controlling member of counterparty Valetudo. Nasdaq delisting notice followed the announcement. |
Three actions to brief before next cycle:
Pull comps | → | Reprice screens | → | Brief committee |
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss · from PDUFA Pulse